Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 11, 2020 at 08:04 pm
Share
Easywell Biomedicals, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 35.120 million compared to TWD 80.278 million a year ago. Operating loss was TWD 48.829 million compared to TWD 49.979 million a year ago. Net loss was TWD 52.769 million compared to TWD 51.670 million a year ago. Basic loss per share from continuing operations was TWD 0.38 compared to TWD 0.46 a year ago. Basic loss per share was TWD 0.38 compared to TWD 0.47 a year ago. For the nine months, sales was TWD 180.747 million compared to TWD 271.539 million a year ago. Operating loss was TWD 146.558 million compared to TWD 162.048 million a year ago. Net loss was TWD 152.890 million compared to TWD 180.560 million a year ago. Basic loss per share from continuing operations was TWD 1.17 compared to TWD 1.54 a year ago. Basic loss per share was TWD 1.17 compared to TWD 1.68 a year ago.
Easywell Biomedicals Inc. is a Taiwan-based company principally engaged in the research, development, production and sale of raw materials and temperature measurement products. The raw materials are applied in the manufacture of medicament for the treatment of epilepsy, pain and fever, antihypertensive and diuretic, skeletal muscle relaxants, among others. The Company's diagnostic devices include ear thermometers and digital clinical thermometers. The Company distributes its products mainly in Taiwan, the Americas and Europe.
EASYWELL BIOMEDICALS, INC. 
